title: [Serum cardiolipin antibodies in patients with alcoholic cirrhosis].
abstract: OBJECTIVE
  Although portal obstruction is a complication in cirrhosis which is usually associated with hepatocellular carcinoma, its precise neoplastic or thrombotic nature is not easy to determine. Serum antiphospholipid antibodies could be involved in thrombosis-related portal obstruction.
  
  
  METHODS
  The presence of serum anticardiolipid antibodies was investigated by an immunoenzymatic technique in 129 patients with alcoholic cirrhosis, 47 patients with hepatocellular carcinoma with (n = 18) or without (n = 29) portal obstruction, and 82 patients without hepatocellular carcinoma or portal obstruction. Five control groups were included: patients with non alcoholic cirrhosis (n = 21), non cirrhotic alcoholic liver disease (n = 21), chronic viral hepatitis (n = 14), extra-hepatic cholestasis (n = 9), and hypergammaglobulinemia associated with human immunodeficiency virus infection without liver disease (n = 28).
  
  
  RESULTS
  The prevalence of serum anticardiolipid antibodies was 57% in patients with alcoholic cirrhosis, which was significantly different from the prevalence in the control groups which ranged from 0 to 32%. Anticardiolipid antibodies were of IgA isotypes in 90.5% of the cases, mainly related to the degree of liver failure but not to hepatocellular carcinoma or portal obstruction.
  
  
  CONCLUSIONS
  In alcoholic cirrhosis, serum anticardiolipid antibodies do not seem to be related to the pathogenesis of portal obstruction in patients with hepatocellular carcinoma. They could rather reflect liver lesions and immunological dysfunctions.
authors.affiliation: Service d'Hépato-Gastroentérologie, Hôpital Civil, Strasbourg.
authors.forename: A
authors.initials: A
authors.lastname: Gervais
authors.forename: B
authors.initials: B
authors.lastname: Czernichow
authors.forename: L
authors.initials: L
authors.lastname: Grunebaum
authors.forename: M L
authors.initials: ML
authors.lastname: Wiesel
authors.forename: A
authors.initials: A
authors.lastname: Auperin
authors.forename: D
authors.initials: D
authors.lastname: Rivalland
authors.forename: J
authors.initials: J
authors.lastname: Gabanyi
authors.forename: L
authors.initials: L
authors.lastname: Goldstein
authors.forename: J P
authors.initials: JP
authors.lastname: Cazenave
authors.forename: M
authors.initials: M
authors.lastname: Doffoël
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000437:Alcoholism / Q000503:physiopathology; D017153:Antibodies, Anticardiolipin / Q000032:analysis*; D006528:Carcinoma, Hepatocellular / Q000209:etiology / Q000276:immunology; D005260:Female; D006801:Humans; D007132:Immunoglobulin Isotypes / Q000032:analysis; D008104:Liver Cirrhosis, Alcoholic / Q000150:complications / Q000276:immunology*; D008107:Liver Diseases / Q000276:immunology; D017093:Liver Failure / Q000276:immunology; D008113:Liver Neoplasms / Q000209:etiology / Q000276:immunology; D008297:Male; D008875:Middle Aged; D011169:Portal Vein; D013587:Syphilis / Q000276:immunology; D013927:Thrombosis / Q000209:etiology / Q000276:immunology
chemical_list: D017153:Antibodies, Anticardiolipin; D007132:Immunoglobulin Isotypes